Grisnilimab

Modify Date: 2025-08-26 12:59:59

Grisnilimab structure	Common Name	Grisnilimab
	CAS Number	2367001-70-3	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Grisnilimab

Grisnilimab (WT1), a IgG2a monoclonal antibody anti-CD7, is a tumor suppressor involved in the etiology of Wilms' tumor. Grisnilimab regulates the transcription of multiple target genes and may participate in the post-transcriptional processing of RNA[1].

Name	Grisnilimab

Description	Grisnilimab (WT1), a IgG2a monoclonal antibody anti-CD7, is a tumor suppressor involved in the etiology of Wilms' tumor. Grisnilimab regulates the transcription of multiple target genes and may participate in the post-transcriptional processing of RNA[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
References	[1]. Scharnhorst V, et al. WT1 proteins: functions in growth and differentiation. Gene. 2001 Aug 8;273(2):141-61. [2]. Hertler AA, et al. An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys. Cancer Immunol Immunother. 1989;28(1):59-66.

Description

Related Catalog

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

References

[1]. Scharnhorst V, et al. WT1 proteins: functions in growth and differentiation. Gene. 2001 Aug 8;273(2):141-61.

[2]. Hertler AA, et al. An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys. Cancer Immunol Immunother. 1989;28(1):59-66.

No Any Chemical & Physical Properties